35 year old male patient self injecting using a Risankizumab (trade name Skyrizi) pen. Risankizumab is a humanised monoclonal antibody that binds to interleukin 23A (IL-23A) and blocks the activity of pro-inflammatory cytokines. It is used to treat moderate to severe plaque psoriasis and active psoriatic arthritis. | |
Licence : | Droits gérés |
Crédit: | Science Photo Library / Marazzi, Dr. P. |
Taille de l’image : | 6048 px × 4024 px |
Model Release : | Disponible |
Restrictions : |
|